Drugs related to monoamine oxidase activity

Progress in understanding the role of monoamine neurotransmission in pathophysiology of neuropsychiatric disorders was made after the discovery of the mechanisms of action of psychoactive drugs, including monoamine oxidase (MAO) inhibitors. The increase in monoamine neurotransmitter availability, decrease in hydrogen peroxide production, and neuroprotective effects evoked by MAO inhibitors represent an important approach in the development of new drugs for the treatment of mental disorders and neurodegenerative diseases. New drugs are synthesized by acting as multitarget-directed ligands, with MAO, acetylcholinesterase, and iron chelation as targets. Basic information is summarized in this paper about the drug-induced regulation of monoaminergic systems in the brain, with a focus on MAO inhibition. Desirable effects of MAO inhibition include increased availability of monoamine neurotransmitters, decreased oxidative stress, decreased formation of neurotoxins, induction of pro-survival genes and antiapoptotic factors, and improved mitochondrial functions.

[1]  P. Gareri,et al.  Conventional and new antidepressant drugs in the elderly , 2000, Progress in Neurobiology.

[2]  S. Dimauro,et al.  Therapeutic prospects for mitochondrial disease. , 2010, Trends in molecular medicine.

[3]  Z. Fišar Pathophysiology of Mood Disorders and Mechanisms of Action of Antidepressants and Mood Stabilizers , 2013 .

[4]  Alessandro Serretti,et al.  Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research , 2013, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[5]  R. Malenka,et al.  Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms , 2008, Neuropsychopharmacology.

[6]  C. Robert Cloninger,et al.  Association of monoamine oxidase (MAO) activity with alcoholism and alcoholic subtypes. , 1993, American journal of medical genetics.

[7]  W Poewe,et al.  Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease , 2006, European journal of neurology.

[8]  Z. Fišar,et al.  Neurotransmission in Mood Disorders , 2012 .

[9]  R. Maj,et al.  Safinamide , 2006, Neurology.

[10]  L. Siever,et al.  Biological Markers for Schizophrenia and the Biological High‐Risk Approach , 1985, The Journal of nervous and mental disease.

[11]  C. Andrade,et al.  Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications , 2010, Mens Sana Monographs.

[12]  M. Beal,et al.  Mitochondrial diseases of the brain. , 2013, Free radical biology & medicine.

[13]  X. Ou,et al.  Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Youdim,et al.  Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression , 2002, Psychopharmacology.

[15]  A. Andreazza,et al.  An updated meta-analysis of oxidative stress markers in bipolar disorder , 2014, Psychiatry Research.

[16]  M. Mattson,et al.  Mitochondria in Neuroplasticity and Neurological Disorders , 2008, Neuron.

[17]  David S. Miller,et al.  Neuropsychiatric symptoms in Alzheimer’s disease , 2011, Alzheimer's & Dementia.

[18]  K. Lim,et al.  Parkin Regulation and Neurodegenerative Disorders , 2016, Front. Aging Neurosci..

[19]  Dennis S. Charney,et al.  Neurobiological mechanisms in major depressive disorder , 2009, Canadian Medical Association Journal.

[20]  Yun-Fai Chris Lau,et al.  Regulation of monoamine oxidase A by the SRY gene on the Y chromosome , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  T. Morrison,et al.  The role of serotonin, vasopressin, and serotonin/vasopressin interactions in aggressive behavior. , 2014, Current topics in behavioral neurosciences.

[22]  J. V. van Amsterdam,et al.  Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. , 2006, Life sciences.

[23]  Xingshu Li,et al.  Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. , 2012, Journal of medicinal chemistry.

[24]  P. Gillman,et al.  Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction , 2007, British journal of pharmacology.

[25]  M. Youdim,et al.  Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness , 2006, British journal of pharmacology.

[26]  Irene Bolea,et al.  Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.

[27]  M. Naoi,et al.  Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. , 2012, Current topics in medicinal chemistry.

[28]  Hayley M. Dorfman,et al.  Neurobiological mechanisms for impulsive-aggression: the role of MAOA. , 2014, Current topics in behavioral neurosciences.

[29]  M. Bourin,et al.  Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder , 2007, Acta psychiatrica Scandinavica. Supplementum.

[30]  Wayne C. Drevets,et al.  Neuroreceptor imaging in depression , 2013, Neurobiology of Disease.

[31]  Tadafumi Kato,et al.  Mitochondrial Dysfunction as the Molecular Basis of Bipolar Disorder , 2007, CNS Drugs.

[32]  F. Stocchi,et al.  Rasagiline for the treatment of Parkinson’s disease: an update , 2015, Expert opinion on pharmacotherapy.

[33]  M. Weinstock,et al.  Ladostigil prevents age-related glial activation and spatial memory deficits in rats , 2011, Neurobiology of Aging.

[34]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[35]  M. Youdim,et al.  Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor , 2003, Neuroscience Letters.

[36]  M. Liebowitz,et al.  Pharmacological treatment of social anxiety disorder: A meta‐analysis , 2003, Depression and anxiety.

[37]  M. Sawada,et al.  Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. , 2006, Journal of neural transmission. Supplementum.

[38]  H. Möller,et al.  Recent progress in pharmacological and non-pharmacological treatment options of major depression. , 2006, Current pharmaceutical design.

[39]  N. Akula,et al.  Genetic Variation in Cholinergic-Muscarinic-2 Receptor Gene Modulates Muscarinic2-Receptor Binding In Vivo and Accounts for Reduced Binding in Bipolar Disorder , 2010, Molecular Psychiatry.

[40]  A. Schrag,et al.  Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson’s Disease , 2008, CNS drugs.

[41]  B. Gutiérrez,et al.  High‐activity variants of the uMAOA polymorphism increase the risk for depression in a large primary care sample , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[42]  B. Devlin,et al.  Haplotypes of the monoamine oxidase genes and the risk for substance use disorders , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[43]  W. Burkard,et al.  Biochemistry and pharmacology of moclobemide, a prototype RIMA , 2005, Psychopharmacology.

[44]  M. Weinstock,et al.  Ladostigil prevents gliosis, oxidative–nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats , 2007, Neuropharmacology.

[45]  A. Takahashi,et al.  Neurogenetics of aggressive behavior: studies in rodents. , 2014, Current topics in behavioral neurosciences.

[46]  A. Serretti,et al.  The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions , 2008, Molecular Psychiatry.

[47]  S. Stahl,et al.  Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants , 2008, CNS Spectrums.

[48]  N. Uysal,et al.  Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. , 2006, Physiological research.

[49]  X. Ou,et al.  Monoamine oxidases in major depressive disorder and alcoholism. , 2012, Drug discoveries & therapeutics.

[50]  Sylvain Houle,et al.  Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  M. Gioulis,et al.  Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature , 2013, Neurology and Therapy.

[52]  F. Owen,et al.  Dopamine is a monoamine oxidase B substrate in man , 1977, Nature.

[53]  M. Youdim,et al.  Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. , 2010, Current Alzheimer research.

[54]  R. Duman Synaptic plasticity and mood disorders , 2002, Molecular Psychiatry.

[55]  P. Riederer,et al.  Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression , 2016, Journal of Neural Transmission.

[56]  P. Tyrer,et al.  Monoamine oxidase inhibitors in anxiety disorders. , 1988, Journal of psychiatric research.

[57]  G. Wegener,et al.  Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. , 2012, Toxicology and applied pharmacology.

[58]  P. Riederer,et al.  Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study. , 1986, Journal of neural transmission. Supplementum.

[59]  Michael Shannon,et al.  The serotonin syndrome. , 2005, The New England journal of medicine.

[60]  D. Edmondson Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. , 2014, Current pharmaceutical design.

[61]  X. Ou,et al.  Glucocorticoid and Androgen Activation of Monoamine Oxidase A Is Regulated Differently by R1 and Sp1* , 2006, Journal of Biological Chemistry.

[62]  K. Merikangas,et al.  Combination monoamine oxidase inhibitor and β-blocker treatment of migraine, with anxiety and depression , 1995, Biological Psychiatry.

[63]  L. Reichardt,et al.  Neurotrophin-regulated signalling pathways , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[64]  Sylvain Houle,et al.  Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. , 2006, Archives of general psychiatry.

[65]  A. Gjedde,et al.  Parkinson's disease and mitochondrial gene variations: A review , 2014, Journal of the Neurological Sciences.

[66]  Reinhard Heun,et al.  Depression in Alzheimer’s disease: is there a temporal relationship between the onset of depression and the onset of dementia? , 2002, European Psychiatry.

[67]  J. P. Petzer,et al.  Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. , 2010, Bioorganic & medicinal chemistry.

[68]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[69]  J. E. Villafranca,et al.  Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol , 2011, PloS one.

[70]  M. Maes,et al.  Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression , 2012, Neuroscience & Biobehavioral Reviews.

[71]  M. Berk,et al.  eview athways underlying neuroprogression in bipolar disorder : Focus on nflammation , oxidative stress and neurotrophic factors , 2010 .

[72]  Irene Bolea,et al.  Propargylamine-derived multitarget-directed ligands: fighting Alzheimer’s disease with monoamine oxidase inhibitors , 2013, Journal of Neural Transmission.

[73]  P. Riederer,et al.  Monoamine oxidase-B inhibition in Alzheimer's disease. , 2004, Neurotoxicology.

[74]  R. Duman Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression , 2009, Dialogues in clinical neuroscience.

[75]  M. Trivedi,et al.  Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression , 1999, Neuropsychopharmacology.

[76]  K. Nunn,et al.  Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa , 2005, European Journal of Human Genetics.

[77]  E. Hirsch,et al.  Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? , 1996, Neurology.

[78]  H. Manji,et al.  Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder , 2006, Biological Psychiatry.

[79]  N. Kato,et al.  Mitochondrial dysfunction in bipolar disorder. , 2000, Bipolar disorders.

[80]  S. Mandel,et al.  Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives , 2005, Brain Research Reviews.

[81]  S. Ross,et al.  Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. , 1986, Biochemical pharmacology.

[82]  Ana Cristina Andreazza,et al.  The role of neurotrophins in bipolar disorder , 2015, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[83]  M. Youdim,et al.  Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  Vedrana Filić,et al.  Monoamine oxidases A and B gene polymorphisms in migraine patients , 2005, Journal of the Neurological Sciences.

[85]  A. Mattevi,et al.  Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. , 2014, Biochimica et biophysica acta.

[86]  A. Urbani,et al.  NMDARs Mediate the Role of Monoamine Oxidase A in Pathological Aggression , 2012, The Journal of Neuroscience.

[87]  J. Shih,et al.  Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.

[88]  K. Swartz,et al.  The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice , 2004, Journal of psychiatric practice.

[89]  L. Oreland,et al.  Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity , 2012, Psychiatric genetics.

[90]  M. Youdim,et al.  Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. , 2004, Journal of medicinal chemistry.

[91]  U. Bonnet Moclobemide: therapeutic use and clinical studies. , 2003, CNS drug reviews.

[92]  A. Mattevi,et al.  Structural properties of human monoamine oxidases A and B. , 2011, International review of neurobiology.

[93]  Oliver Wirths,et al.  Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease , 2014, Acta Neuropathologica.

[94]  T. Nag,et al.  Activity-dependent synaptic plasticity modulates the critical phase of brain development , 2016, Brain and Development.

[95]  Karmen K. Yoder,et al.  Striatal dopamine transporter availability in unmedicated bipolar disorder. , 2011, Bipolar disorders.

[96]  Y. Will,et al.  Current Concepts in Drug‐Induced Mitochondrial Toxicity , 2009, Current protocols in toxicology.

[97]  A. Andreazza,et al.  Current State of Biomarkers in Bipolar Disorder , 2014, Current Psychiatry Reports.

[98]  Maria Laura Bolognesi,et al.  Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease , 2011, Neurotherapeutics.

[99]  K. Kuča,et al.  Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitarget‐Directed Ligands for the Treatment of Alzheimer's Disease , 2016, ChemMedChem.

[100]  Tadafumi Kato,et al.  Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. , 2008, Cell calcium.

[101]  C. Perry,et al.  Rasagiline , 2012, Drugs.

[102]  Li Wang,et al.  Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.

[103]  Jie-shi Zhang,et al.  Study of a possible role of the monoamine oxidase A (MAOA) gene in paranoid schizophrenia among a Chinese population , 2012, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[104]  J. Finberg Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. , 2014, Pharmacology & therapeutics.

[105]  P. Renshaw,et al.  Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research , 2005, Molecular Psychiatry.

[106]  R. Belmaker,et al.  Major depressive disorder. , 2008, The New England journal of medicine.

[107]  A. Cavalli,et al.  Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease , 2013, PloS one.

[108]  Wei Huang,et al.  Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[109]  S. Ross,et al.  Selective monoamine oxidase inhibitors. 4. 4-Aminophenethylamine derivatives with neuron-selective action. , 1986, Journal of medicinal chemistry.

[110]  S. Ross,et al.  Selective inhibition of monoamine oxidase by p-aminosubstituted phenylalkylamines in catecholaminergic neurones , 1986, Neuropharmacology.

[111]  E. Masliah,et al.  Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant , 2002, Neuroscience Letters.

[112]  Gerta Rücker,et al.  Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis , 2015, The Annals of Family Medicine.

[113]  Y. Qian,et al.  Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. , 2001, American journal of medical genetics.

[114]  P. Seeburg,et al.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[115]  Lisa Goehler,et al.  Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. , 2011, Neuro endocrinology letters.

[116]  S. Choi,et al.  R1, a Novel Repressor of the Human Monoamine Oxidase A* , 2005, Journal of Biological Chemistry.

[117]  V. Zurawski,et al.  Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging , 2015, Neurobiology of Aging.

[118]  R. Duman,et al.  Chronic Antidepressant Administration Increases the Expression of Camp-specific Phosphodiesterase 4a and 4b Isoforms , 1998 .

[119]  Z. Fišar Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[120]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[121]  J. Schildkraut,et al.  The catecholamine hypothesis of affective disorders. A review of supporting evidence. , 1967, International journal of psychiatry.

[122]  M. Carrillo,et al.  Why (−)deprenyl prolongs survivals of experimental animals: Increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects , 2002, Mechanisms of Ageing and Development.

[123]  L. Olson,et al.  Mitochondrial and Ubiquitin Proteasome System Dysfunction in Ageing and Disease: Two Sides of the Same Coin? , 2015, International journal of molecular sciences.

[124]  P. Trebon,et al.  Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline , 2005, Psychopharmacology.

[125]  Y. Oh,et al.  Promise of Neurorestoration and Mitochondrial Biogenesis in Parkinson's Disease with Multi Target Drugs: An Alternative to Stem Cell Therapy , 2013, Experimental neurobiology.

[126]  Z. Cai Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). , 2014, Molecular medicine reports.

[127]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[128]  Xi Chen,et al.  An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease , 1997, Nature.

[129]  P. Malherbe,et al.  Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry , 1996, Neuroscience.

[130]  Alan A. Wilson,et al.  Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[131]  S. Hyman,et al.  Neural mechanisms of addiction: the role of reward-related learning and memory. , 2006, Annual review of neuroscience.

[132]  L. Siever Neurobiology of aggression and violence. , 2008, The American journal of psychiatry.

[133]  T. Mohandas,et al.  Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease. , 1989, Genomics.

[134]  A. Coppen The Biochemistry of Affective Disorders , 1967, British Journal of Psychiatry.

[135]  L. Siever,et al.  The neurobiology of aggression and violence , 2015, CNS Spectrums.

[136]  M. Youdim,et al.  TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. , 2000, Journal of neural transmission. Supplementum.

[137]  Y. Kumar,et al.  Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles. , 1986, Journal of medicinal chemistry.

[138]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[139]  D. Swaab,et al.  A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients , 2007, Brain Research.

[140]  A. Mattevi,et al.  Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. , 2009, Biochemistry.

[141]  E. Nestler,et al.  A molecular and cellular theory of depression. , 1997, Archives of general psychiatry.

[142]  S. Mandel,et al.  From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[143]  R. Ramsay,et al.  2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. , 2010, Bioorganic & medicinal chemistry.

[144]  C. Counsell,et al.  Monoamine oxidase B inhibitors for early Parkinson's disease. , 2005, The Cochrane database of systematic reviews.

[145]  Z. Fišar,et al.  Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. , 2010, Neuro endocrinology letters.

[146]  G. Nowak,et al.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors , 2012, Inflammopharmacology.

[147]  H. Manji,et al.  Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. , 2007, CNS & neurological disorders drug targets.

[148]  D. Charney,et al.  The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. , 1996, Pharmacopsychiatry.

[149]  Hyoung-Gon Lee,et al.  Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass , 2014, Neuroscience Bulletin.

[150]  J. Shih,et al.  Transcriptional regulation and multiple functions of MAO genes , 2011, Journal of Neural Transmission.

[151]  M. Youdim Rasagiline: an anti-Parkinson drug with neuroprotective activity , 2003, Expert review of neurotherapeutics.

[152]  M. Youdim,et al.  Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β‐amyloid in ageing and Alzheimer's disease , 2016, British journal of pharmacology.

[153]  R. Ramsay,et al.  An improved approach to steady-state analysis of monoamine oxidases , 2011, Journal of Neural Transmission.

[154]  M. Youdim,et al.  The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. , 2006, Antioxidants & redox signaling.

[155]  Song-Yu Yang,et al.  Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[156]  D. Lahiri,et al.  Metal and inflammatory targets for Alzheimer's disease. , 2004, Current drug targets.

[157]  D. Lynam,et al.  Monoamine oxidase A (MAOA) genotype predicts greater aggression through impulsive reactivity to negative affect , 2015, Behavioural Brain Research.

[158]  Xingshu Li,et al.  A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. , 2013, European journal of medicinal chemistry.

[159]  A. Duong,et al.  Biomarkers for bipolar disorder: current insights , 2015 .

[160]  M. Youdim,et al.  Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases , 2004, Journal of Neural Transmission.

[161]  T. Patil,et al.  Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson's disease , 2013, Indian journal of pharmacology.

[162]  Roy W Jones,et al.  Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease , 2012, Expert review of neurotherapeutics.

[163]  D. Mousseau,et al.  An update on amine oxidase inhibitors: Multifaceted drugs , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[164]  R. Ramsay,et al.  Monoamine oxidases: to inhibit or not to inhibit. , 2003, Mini reviews in medicinal chemistry.

[165]  A. Goodman Neurobiology of addiction. An integrative review. , 2008, Biochemical pharmacology.

[166]  A. Caspi,et al.  Role of Genotype in the Cycle of Violence in Maltreated Children , 2002, Science.

[167]  M. Mesulam Neuroplasticity Failure in Alzheimer's Disease Bridging the Gap between Plaques and Tangles , 1999, Neuron.

[168]  S. Henriot,et al.  Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. , 1994, Journal of neural transmission. Supplementum.

[169]  P. Lazarovici,et al.  Neuroprotective Effects of Novel Cholinesterase Inhibitors Derived from Rasagiline as Potential Anti‐Alzheimer Drugs , 2001, Annals of the New York Academy of Sciences.

[170]  W. Drevets,et al.  Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. , 2006, Archives of general psychiatry.

[171]  Sheridan M. Hoy,et al.  Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. , 2012, Drugs.

[172]  M. Youdim,et al.  Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil , 2007, Annals of the New York Academy of Sciences.

[173]  K. Kuča,et al.  In vitro effects of acetylcholinesterase reactivators on monoamine oxidase activity. , 2011, Toxicology letters.

[174]  C. Pittenger,et al.  Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms , 2008, Neuropsychopharmacology.

[175]  K. Shulman,et al.  Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression , 2013, CNS Drugs.

[176]  M. Austin,et al.  Mechanistic Role for a Novel Glucocorticoid-KLF11 (TIEG2) Protein Pathway in Stress-induced Monoamine Oxidase A Expression* , 2012, The Journal of Biological Chemistry.

[177]  P. Benfield,et al.  Moclobemide. An update of its pharmacological properties and therapeutic use. , 1996 .

[178]  Ying Yang,et al.  Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. , 2010, Bioorganic & medicinal chemistry.

[179]  Peter V Coveney,et al.  Monotopic enzymes and lipid bilayers: a comparative study. , 2007, Biochemistry.

[180]  Subrata K. Bose,et al.  Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB , 2011, Psychopharmacology.

[181]  S. Esteban,et al.  Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[182]  C. Pérez,et al.  Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro. , 2013, Current Alzheimer research.

[183]  Z. Fišar Inhibition of monoamine oxidase activity by cannabinoids , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[184]  Ana Martínez,et al.  Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease , 2006, Expert opinion on investigational drugs.

[185]  P. Gillman,et al.  Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[186]  K. Tipton,et al.  The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. , 1988, Journal of neural transmission. Supplementum.

[187]  Ronald S Duman,et al.  NEUROBIOLOGY OF STRESS, DEPRESSION, AND RAPID ACTING ANTIDEPRESSANTS: REMODELING SYNAPTIC CONNECTIONS , 2014, Depression and anxiety.

[188]  M. Youdim,et al.  Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. , 2010, Current Alzheimer research.

[189]  J. Meyer,et al.  Neuroimaging Markers of Cellular Function in Major Depressive Disorder: Implications for Therapeutics, Personalized Medicine, and Prevention , 2012, Clinical pharmacology and therapeutics.

[190]  G. Chouinard,et al.  Moclobemide Update of its Pharmacological Properties and Therapeutic Use , 1996 .

[191]  M. Nelen,et al.  Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. , 1993, Science.

[192]  Alan A. Wilson,et al.  Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. , 2009, Archives of general psychiatry.

[193]  M. Naoi,et al.  Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase , 2004, InflammoPharmacology.

[194]  T. Hergueta,et al.  Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. , 1990, British journal of clinical pharmacology.

[195]  Carlos A. Zarate,et al.  Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder , 2006, Biological Psychiatry.

[196]  V. Chekhonin,et al.  Genetic determinants of aggression and impulsivity in humans , 2012, Journal of Applied Genetics.

[197]  Z. Fišar,et al.  Intracellular signalling pathways and mood disorders. , 2010, Folia biologica.

[198]  G. Demaagd,et al.  Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. , 2015, P & T : a peer-reviewed journal for formulary management.

[199]  J. Mann,et al.  An Association between a Functional Polymorphism in the Monoamine Oxidase A Gene Promoter, Impulsive Traits and Early Abuse Experiences , 2004, Neuropsychopharmacology.

[200]  N. Craddock,et al.  Association studies of bipolar disorder. , 2001, Bipolar disorders.

[201]  J. Jankovic,et al.  Variability and validity of polymorphism association studies in Parkinson’s disease , 2000, Neurology.

[202]  D. Rujescu,et al.  Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[203]  A. Holt,et al.  On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. , 2004, Neurotoxicology.

[204]  P. Söderkvist,et al.  G/A polymorphism in intronic sequence affects the processing of MAO‐B gene in patients with Parkinson disease , 2012, FEBS letters.

[205]  S. Channon,et al.  The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. , 1995, Journal of clinical psychopharmacology.

[206]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.

[207]  J. Krystal,et al.  MAOA Genotype, Maltreatment, and Aggressive Behavior: The Changing Impact of Genotype at Varying Levels of Trauma , 2009, Biological Psychiatry.

[208]  Namrata Singh,et al.  Mitochondrial Dysfunctions in Neurodegenerative Diseases: Relevance to Alzheimer's Disease , 2014, BioMed research international.

[209]  L. Oreland,et al.  Platelet MAO and personality--function and dysfunction. , 2004, Current medicinal chemistry.

[210]  J. Thome,et al.  cAMP Response Element-Mediated Gene Transcription Is Upregulated by Chronic Antidepressant Treatment , 2000, The Journal of Neuroscience.

[211]  Wenhua Liu,et al.  Parkin Suppresses the Expression of Monoamine Oxidases* , 2006, Journal of Biological Chemistry.

[212]  G. Fazio,et al.  Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders , 2010 .

[213]  S. Yan,et al.  Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction. , 2014, Current Alzheimer research.

[214]  J. Schildkraut,et al.  Platelet monoamine oxidase activity and deficit syndrome schizophrenia , 1995, Psychiatry Research.

[215]  R. Nelson,et al.  Nitric oxide and serotonin interactions in aggression. , 2014, Current topics in behavioral neurosciences.

[216]  P. Riederer,et al.  A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease , 2004, Neurology.

[217]  M. Mattson,et al.  Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. , 2010, Antioxidants & redox signaling.

[218]  M. Radicioni,et al.  Pressor Response to Oral Tyramine and Monoamine Oxidase Inhibition During Treatment with Ralfinamide (NW-1029) , 2012, Neurotoxicity Research.

[219]  H. Hampel,et al.  Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics , 2011, Journal of Neural Transmission.

[220]  M. Maj,et al.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression , 2009, Metabolic Brain Disease.

[221]  Christophe Mulle,et al.  Activity‐dependent synaptic plasticity of NMDA receptors , 2010, The Journal of physiology.